In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CV Therapeutics sells off 50% of its NA Lexiscan royalties

Executive Summary

CV Therapeutics (cardiovascular disease) has sold TPG-Axon Capital 50% of the North American royalties from Lexiscan (regadenoson) injection for $175mm up front plus a $10mm commercialization milestone.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies